{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-014811","form_type":"8-K","ticker":"FLGT","cik":"0001674930","company_name":"Fulgent Genetics, Inc.","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.617332+00:00","generated_at":"2026-06-24T04:14:43.741626+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Fulgent Genetics Q2 revenue $125.3M; core revenue up 102% YoY, guidance raised","bullets":["Total revenue $125.3M (Q2 2021: $153.6M); billable tests 1.3M (vs 1.6M).","Core revenue (ex-COVID) $45.3M, +102% YoY; full-year core revenue guidance raised to $185M from $180M.","GAAP net income $11.5M ($0.37/share); non-GAAP net income $24.3M ($0.78/share); adjusted EBITDA $37.7M.","Cash & marketable securities $931M as of June 30, 2022.","Strong growth in genetic testing beyond COVID driving core revenue expansion."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-014811","json":"https://secwatch.observer/filing/0000950170-22-014811.json","markdown":"https://secwatch.observer/filing/0000950170-22-014811.md","text":"https://secwatch.observer/filing/0000950170-22-014811.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674930/000095017022014811/0000950170-22-014811-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674930/000095017022014811/flgt-20220804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:14:43.741626+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}